FENNEC PHARMACEUTICALS INC
FENCNASDAQ🏆 #2386 by market capEarnings Aug 11 · PreUS Equity
$167.56▼ $11.91 (−7.11%)
Simulated price1h—
24h▼ 7.1%
7d—
14d—
30d—
1y—
🏦Market Cap
$380M
Small Cap
📈Revenue Growth (YoY)
+33.8%
High Growth
📊Gross Margin
92.8%
High
💵FCF Margin
—
⚖️P/S Ratio
9.3x
Elevated
Otter Score
44
Weak
No chart data available for FENC.
Trading Snapshot
- Day Range
- $165.56 – $170.64
- 52-Week Range
- $5.65 – $11.66
- Volume
- $3.59B
- Avg Volume
- $4.76B
- Shares Outstanding
- 34.7M
- Next Earnings
- Sep 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $41M
- Last Q Revenue
- $11M
- P/E Ratio
- —
- P/S Ratio
- 9.3x
- EPS (TTM)
- $-0.28
- Dividend Yield
- —
Why Investors Own FENC
- ✓High-growth profile — revenue up +25.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 34% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$41M▲ +30.6% YoY
Gross Margin (TTM)
33.9%▲ +0.9% YoY
Operating Income (TTM)
$12M▲ +30.6% YoY
Free Cash Flow (TTM)
$10M▲ +30.6% YoY
About FENNEC PHARMACEUTICALS INC
A company profile for FENNEC PHARMACEUTICALS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
44/100
Analyst Price Target
ⓘAverage Target
$192.98
▲ +15.2% Upside
High Target$238.28
Low Target$177.68
Based on 21 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
FENNEC PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift FENC price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
FENNEC PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.